Log In
Print
BCIQ
Print
Print this Print this
 

R256

  Manage Alerts
Collapse Summary General Information
Company Rigel Pharmaceuticals Inc.
DescriptionInhaled interleukin-13 (IL-13) signaling and JAK kinase (JAK) inhibitor
Molecular Target Interleukin-13 (IL-13) ; JAK kinase (JAK)
Mechanism of ActionJanus kinase inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPreclinical
Standard IndicationAsthma
Indication DetailsTreat chronic asthma
Regulatory Designation
Partner AstraZeneca plc

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$100.0M

$1.0M

$99.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today